The PI of this project was: Christos Kyriakopoulos, MD

This project was funded by: Non-Federal

The term of this project was: May 2018 to May 2019

The number of subjects scanned during this project was: 10

The overall goal of this study is to examine whether the addition of cabazitaxel to abiraterone acetate can improve the overall response as well as the percentage of responding lesions compared to abiraterone acetate alone in prostate cancer. All participants will receive two imaging studies according to study protocol: pre-treatment NaF PET/CT at baseline and a mid-treatment NaF PET/CT at week 12. The goal is to characterize the pharmacodynamic changes and response to treatment using NaF PET/CT